The FDA's Aducanumab Disaster | Psychology Today

[anonymous]

The FDA's Aducanumab Disaster | Psychology Today

https://www.psychologytoday.com/us/blog/american-dementia/202110/the-fdas-aducanumab-disaster

KEY POINTS

• Aducanumab is an antibody that removes amyloid molecules associated with Alzheimer's disease.
• The drug was approved by the FDA in spite of showing a lack of adequate clinical efficacy and causing brain bleeds and swelling.
• There have been serious concerns about possible ethical improprieties at the heart of aducanumab’s approval.

Since the Food and Drug Administration (FDA) approved Biogen’s drug aducanumab (marketed as Aduhelm) on June 7, it has been quite a bumpy ride on a predominantly downhill slope. We thought we’d do a quick check-in about our concerns over the controversial biologic and speculate as to where things might be going.

 

[anonymous]

Any updates?

 

[anonymous]

None

 

[anonymous]

It’s a train wreck. Thanks Alex Scott for the stellar biz development work.